Integra LifeSciences Prices $450 Mln Of 9.5% Senior Secured Notes Due 2033

Integra LifeSciences Holdings completed a $450 million senior secured notes offering on 10/19/2026. The company's stock has seen a 5-day change of +1.82% and a year-to-date change of +8.29%. Previously, Truist Securities adjusted its price target to $15 from $19.

Integra LifeSciences (IART) raised $2.1B on Oct 19, 2026, via new credit facilities and a notes offering. The company secured $1.65B in senior secured credit facilities and $450M in 9.500% senior secured notes due 2033. Proceeds were used to repay and terminate the 2023 credit agreement, enhancing liquidity and extending debt maturities.

Integra LifeSciences (IART) closed a $450M 9.5% notes offering due 2033 and amended its credit facility to ~$1.65B, including a $600M revolver and $1.05B in term loans. Proceeds refinanced debt and paid fees, according to the company.

Integra LifeSciences priced $450 million in senior secured notes due in 2033. The company's stock has seen a 5.99% increase over the past year, with a recent 0.22% gain. The article also includes various composite ratings for the company, covering valuation, earnings revisions, and visibility.

Integra LifeSciences (IART) priced $450M in 9.5% senior secured notes due 2033, expected to close by October 19. Proceeds will refinance debt and support new borrowings. The company trades at a P/S ratio of 0.64, below historical and industry norms, and has a GF Score of 69, indicating mixed financial health.

Integra LifeSciences (IART) priced $450M in senior secured notes with a 9.500% coupon, maturing in 2033. Proceeds will refinance existing credit arrangements. The company expects higher financing costs. Analysts rate IART as Hold with a $15 target. Spark's AI rates it Neutral due to weak financials and bearish technicals.